ArticleOpen research Europe2025
When artificial intelligence meets protein research.
Article in Open research Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence Across the Drug Development Lifecycle.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2024 Nobel Prizes in Chemistry and Physics mark a watershed moment in the convergence of artificial intelligence (AI) and molecular biology. This article explores how AI, particularly deep learning and neural networks, has revolutionized protein science through breakthroughs in structure prediction and computational design. It highlights the contributions of 2024 Nobel laureates John Hopfield, Geoffrey Hinton, David Baker, Demis Hassabis, and John Jumper, whose foundational work laid the groundwork for AI tools such as AlphaFold. These tools are transforming our understanding of protein folding, and the dynamics of non-globular proteins, including intrinsically disordered proteins. While AI-driven methods have made predicting protein structures faster and more accessible, they also underscore ongoing scientific challenges, including the dynamics of protein folding and amyloid aggregation. European initiatives, such as the COST Actions NGP-net (BM1405) and ML4NGP (CA21160), are spearheading efforts to bridge these gaps by integrating AI and experimental data in the study of non-globular proteins. Together, these developments signal a transformative shift in biology, paving the way for novel discoveries in medicine, biotechnology, and materials science.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.